Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

99.02% of the stock is owned by institutional investors and hedge funds. Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and ...

Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

Myriad Genetics, Inc. announced that its MyRisk® Hereditary Cancer Test with RiskScore® was recognized in the American Journal of Human Genetics as one of the top 10 significant advances in ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who ...

As an ambassador for Myriad's Breast Cancer Risk Assessment Program, Storm will promote the MyRisk® with RiskScore® Hereditary Cancer Test, which evaluates genetic risks for various cancers.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a ...

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for ...

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that ...